CaroGen Corp
About Us

CaroGen Highlights

AVIDIO Platform

Read More

Oncology: CARG-2020

Read More

Infectious Disease: CARG-201

Read More
CaroGen Corp
OUR TEAM

Senior Management and Founders

CaroGen Corp

Bijan Almassian, PhD

Co-Founder, President & CEO Board of Directors

CaroGen Corp

John Rose, PhD

Co-Founder and Chairman of the SAB

CaroGen Corp

Michael Robek, PhD

Co-Founder, Member of SAB

CaroGen Corp

Valerian Nakaar, PhD

Co-Founder, CSO, Sr. Vice President Board of Directors

OUR PRESS RELEASES

CaroGen News

CaroGen Corp

CaroGen Management to Speak at The World Vaccine Immunotherapy Congress

Farmington, CT, September 5, 2022– CaroGen Corporation (https://carogencorp.com), a developer of trans-formative immunotherapies for cancer and infectious diseases, today announced that Bijan Almassian, PhD, President & CEO, and Timur Yarovinsky, MD, PhD, Vice President of Discovery

CaroGen Corp

Bijan Almassian, PhD. on LinkedIn: CaroGen in pact with NIH...

We are honored to be working with NIAID/NIH scientists to develop a universal influenza vaccine.

CaroGen Corp

“Relational Contract” Supports Outsourcing Of Hepatitis B Immunotherapy

Striving to develop CARG-201 as a novel immunotherapy for potential functional cure of over 250 million patients worldwide chronically infected with hepatitis B virus (HBV). Currently there is no cure for HBV.

CaroGen Corporation CaroGen Corporation (203) 815-5782 balmassian@carogencorp.com